229 related articles for article (PubMed ID: 29426830)
1. Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation.
Pandit A; Leblebjian H; Hammond SP; Laubach JP; Richardson PG; Baden LR; Marty FM; Issa NC
Bone Marrow Transplant; 2018 Jul; 53(7):942-945. PubMed ID: 29426830
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
Huang J; Phillips S; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Jagasia M; Kassim A; Rawling KT; Savani BN; Sengsayadeth S; Cornell RF
Bone Marrow Transplant; 2018 Jun; 53(6):701-707. PubMed ID: 29703965
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
4. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.
Croce E; Hatz C; Jonker EF; Visser LG; Jaeger VK; Bühler S
Vaccine; 2017 Mar; 35(9):1216-1226. PubMed ID: 28162821
[TBL] [Abstract][Full Text] [Related]
5. Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant.
Desjardins M; Mitre X; Sherman AC; Walsh SR; Cheng MP; Kanjilal S; Ho VT; Baden LR; Issa NC
Open Forum Infect Dis; 2021 Dec; 8(12):ofab504. PubMed ID: 34909436
[TBL] [Abstract][Full Text] [Related]
6. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Bumma N; Dhakal B; Fraser R; Estrada-Merly N; Anderson K; Freytes CO; Hildebrandt GC; Holmberg L; Krem MM; Lee C; Lekakis L; Lazarus HM; Mian H; Murthy HS; Nathan S; Nishihori T; Parrondo R; Patel SS; Solh M; Strouse C; Vesole DH; Kumar S; Qazilbash MH; Shah N; D'Souza A; Sidana S
Cancer; 2023 Jul; 129(14):2179-2191. PubMed ID: 37021929
[TBL] [Abstract][Full Text] [Related]
7. Safety and Seropositivity after Live Attenuated Vaccine in Adult Patients Receiving Hematopoietic Stem Cell Transplantation.
Aoki T; Kamimura T; Yoshida S; Mori Y; Kadowaki M; Kohno K; Ishihara D; Urata S; Sugio T; Kamezaki K; Kato K; Ito Y; Eto T; Akashi K; Miyamoto T
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1576-1585. PubMed ID: 30959161
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma.
Modi D; Chi J; Kim S; Ayash L; Alavi A; Kin A; Ratanatharathorn V; Uberti JP; Deol A
Leuk Lymphoma; 2020 Aug; 61(8):1877-1884. PubMed ID: 32270725
[TBL] [Abstract][Full Text] [Related]
9. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
Chen RW; Palmer JM; Tomassetti S; Popplewell LL; Alluin J; Chomchan P; Nademanee AP; Siddiqi T; Tsai NC; Chen L; Zuo F; Abary R; Cai JL; Herrera AF; Rossi JJ; Rosen ST; Forman SJ; Kwak LW; Holmberg LA
J Hematol Oncol; 2018 Jun; 11(1):87. PubMed ID: 29954415
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma.
Pulte ED; Dmytrijuk A; Nie L; Goldberg KB; McKee AE; Farrell AT; Pazdur R
Oncologist; 2018 Jun; 23(6):734-739. PubMed ID: 29438096
[TBL] [Abstract][Full Text] [Related]
11. Acute auto-aggression syndrome following autologous hematopoietic stem cell transplant and lenalidomide for multiple myeloma.
Struble E; Ginn M; Strouse C
J Oncol Pharm Pract; 2023 Oct; 29(7):1785-1788. PubMed ID: 37401247
[TBL] [Abstract][Full Text] [Related]
12. Risk adapted post-transplant maintenance in multiple myeloma.
Vaxman I; Gertz M
Expert Rev Hematol; 2019 Feb; 12(2):107-118. PubMed ID: 30696304
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R
Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients.
Kawamura K; Yamazaki R; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Hematology; 2015 Mar; 20(2):77-82. PubMed ID: 24992512
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Kaufman JL; Mina R; Shah JJ; Laubach JP; Nooka AK; Lewis C; Gleason C; Sharp C; Harvey RD; Heffner LT; Richardson P; Lonial S; Orlowski RZ
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):797-803. PubMed ID: 32819881
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib.
Ataca Atilla P; Yalçıner M; Atilla E; İdilman R; Beksaç M
Turk J Haematol; 2019 Nov; 36(4):266-273. PubMed ID: 31368290
[TBL] [Abstract][Full Text] [Related]
17. [Risk Factors and the Effect of Antiviral Prophylaxis for Herpes Zoster in Multiple Myeloma Patients].
Wang LX; Ji YP; Lei F; Yu XQ; Fei XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):171-175. PubMed ID: 38387917
[TBL] [Abstract][Full Text] [Related]
18. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
[No Abstract] [Full Text] [Related]
19. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
[TBL] [Abstract][Full Text] [Related]
20. Vaccines for measles, mumps, rubella, varicella, and herpes zoster: immunization guidelines for adults.
Hendriksz T; Malouf P; Foy JE;
J Am Osteopath Assoc; 2011 Oct; 111(10 Suppl 6):S10-2. PubMed ID: 22086887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
